CNS Pharmaceuticals Inc. to Showcase Innovations at Webull Financial Biotech/MedTech Webinar Series

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company at the forefront of developing innovative treatments for primary and metastatic cancers affecting the brain and central nervous system, has announced its participation in the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. This virtual event, scheduled for August 19–21, 2025, will serve as a platform for CNS Pharmaceuticals to share its latest research and developments with investors and the broader medical community.

The company's presentation is expected to focus on its promising drug candidate, TPI 287, an abeotaxane that has shown potential in crossing the blood-brain barrier to treat central nervous system tumors. With clinical trials involving over 350 patients, TPI 287 has demonstrated an excellent safety profile and high tolerability across a range of conditions, including recurrent glioblastoma and metastatic breast cancer to the brain. For more details on CNS Pharmaceuticals' participation in the webinar, visit https://ibn.fm/EOCy9.

This announcement underscores the importance of CNS Pharmaceuticals' work in addressing some of the most challenging cancers, particularly those affecting the brain and central nervous system. The company's focus on developing treatments that can effectively target these hard-to-treat areas represents a significant advancement in oncology research. Investors and healthcare professionals alike will be keen to learn more about the progress of TPI 287 and its implications for future cancer therapies. For ongoing updates and news related to CNS Pharmaceuticals, visit https://ibn.fm/CNSP.